Pr François Ghiringhelli

Spécialité

Oncologue médical, expert digestif

Hôpital

Centre Georges-François Leclerc (Dijon)

Derniers articles

• Co-targeting TGF-β and PD-L1 sensitizes triple-negative breast cancer to experimental immunogenic cisplatin-eribulin chemotherapy doublet. (1 juil. 2025)
• Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trial. (30 juin 2025)
• UCPVax, a CD4 helper peptide vaccine, induces polyfunctional Th1 cells, antibody response, and epitope spreading to improve antitumor immunity. (20 juin 2025)
• Genetic biomarker study of sunvozertinib for clinical prognosis and prediction in NSCLC with EGFR exon 20 insertion mutation. (20 mai 2025)
• The intrinsic expression of NLRP3 in Th17 cells promotes their protumor activity and conversion into Tregs. (1 mai 2025)